First blood-stage malaria vaccine ‘a much-needed addition’ – analyst
Following positive Phase IIb trial results, RH5.1/Matrix-M could be the first blood-stage malaria vaccine brought to market.
Immuno
Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription
Unmet needs in the chronic hand eczema treatment landscape
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
‘Pill-on-a-thread’ cancer screening trial commences with first patients
Barinthus Bio shares ongoing Phase IIb chronic hepatitis B trial results
Lyell goes all in on CAR-T therapies, buys ImmPACT Bio and trims pipeline
